Comunicati Stampa
Salute e Benessere

Diabetes Care Devices Market worth US$61.2 billion by 2030 with 12.3% CAGR | MarketsandMarkets™

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=375 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=375 Browse in-depth TOC on "Diabetes Care Devices Market" 200 - Tables 60 - Figures 250 - Pages By product type,the global diabetes care devices market is divided into three main segments: blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications. The blood glucose...
DELRAY BEACH, Fla., (informazione.news - comunicati stampa - salute e benessere)

the global diabetes care devices market is divided into three main segments: blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications. The blood glucose monitoring systems segment held the largest share of the market, driven by their strong functional benefits and crucial role in supporting effective diabetes management. These devices offer several advantages, such as real-time, continuous glucose data without the need for frequent pricks, which is gaining popularity among patients and healthcare providers. The integration with mobile apps makes it convenient for patients to monitor glucose level fluctuations and make informed decisions about the same.

the global diabetes care devices market is divided into categories based on patient care settings: self/home healthcare and hospitals & diabetes specialty clinics. Among these, the self/home healthcare segment is projected to hold the largest share of the market. Self-monitoring devices allow individuals to manage their conditions at home and reduce the need for frequent hospital or clinic visits. As people age, they prefer to handle their chronic conditions at home and avoid traveling to healthcare facilities. This daily self-management is crucial for preventing acute complications and enhancing long-term health outcomes. The rising global prevalence of diabetes, driven by lifestyle changes and an aging population, results in a large patient base.

, the rapid rise in type 2 diabetes is directly linked to obesity and sedentary lifestyles, especially abdominal fat, which leads to insulin resistance. Global obesity rates have increased due to changes in diet and decreased physical activity. Dietary habits such as consuming processed foods and unhealthy fats have contributed to the development of this condition. The risk is also higher in the aging population, and as the geriatric population grows, the number of individuals with this condition increases.

, the global market for surgical microscopes is divided into six main regions: North America , Europe , the Asia Pacific , Latin America , the Middle East & Africa , and the GCC Countries.

North America leads the diabetes care devices market, supported by a strong healthcare infrastructure, early adoption of advanced formulations, and high consumer demand for preventive and treatment products. The region's dominance is also reinforced by the presence of leading diabetes care device companies based in the US, which drive ongoing innovation and product availability. Elevated disposable income levels and growing health awareness among consumers in the US and Canada contribute to increased use of diabetes care devices. Additionally, the expanding distribution network of dental clinics, pharmacies, and retail outlets, along with continuous product premiumization, further reinforces North America's leadership in the global diabetes care market.

Prominent players in the Diabetes care devices market include F. Hoffmann Roche Ltd ( Switzerland ), Abbott Laboratories (US), Medtronic ( Ireland ), Dexcom (US), Insulet Corporation (US), B Braun Se ( Germany ), Embecta Corp (US), Nipro ( Japan ), Senseonics (US), Ypsomed ( Switzerland ), i-Sens, Inc ( South Korea ), Tandem Diabetes Care, Inc (US), ACON LABORATORIES, INC (US), ARKRAY, INC( Japan ), Terumo Corporation ( Japan ), Sinocare Inc ( Japan ), Waveform Diabetes (AgaMatrix) (US), Lifescan IP Holdings (US), SD Biosensor, Inc ( South Korea ), Debiotech SA. ( Switzerland ), Sungshim Medical Co, Ltd ( South Korea ), Sooil Developments Co., Ltd ( South Korea ), Hindustan syringes and medical devices ( India ), Microgene Diagnostic Systems Pvt Ltd ( India ), Rossmax International Ltd ( Taiwan ).

Among other developments, these companies adopted strategies such as partnerships, collaborations, agreements, integrations, acquisitions, product launches, and expansions to strengthen their presence in the diabetes care devices market.

F. Hoffmann-La Roche Ltd. is a major global leader in the market for diabetes care devices. Roche operates through two segments: Pharmaceuticals and Diagnostics; the company is divided into four main areas: Centralized and Point of Care Solutions, Molecular Diagnostics, Tissue Diagnostics, and Diabetes Care. The Diabetes Care segment offers a variety of devices and solutions for effective diabetes management. A flagship product in this segment is the Accu-Chek blood glucose meter, widely recognized and clinically recommended for blood glucose monitoring. Accu-Chek devices are trusted by both patients and healthcare professionals for their accuracy, reliability, and strong clinical validation, making them a key part of Roche's diabetes care portfolio and essential in managing diabetes effectively.

Abbott Laboratories a leading global healthcare company founded in 1888 and headquartered in Illinois , US, is a major player in the diabetes care devices market. The company has a strong tradition of innovation by operating in multiple key sectors, including pharmaceuticals, nutrition, diagnostics, and medical technologies. A core part of its success is its leadership in diabetes care. Through its flagship FreeStyle brand, Abbott provides a range of advanced continuous glucose monitoring (CGM) and blood glucose systems, most notably the FreeStyle Libre, along with essential accessories and digital health tools for patients around the world. With a workforce exceeding 114,000 and a presence in over 160 countries, the company uses its diverse portfolio and extensive global reach to stay a highly trusted name in health and wellness.

Medtronic is a global leader in medical technology and has been at the forefront of health technology since its founding in 1949. It also controlled a significant share of the diabetes care devices market in 2024. Headquartered in Dublin, Ireland , the company's core mission is to alleviate pain, restore health, and extend life. With operations in over 150 countries and a workforce of more than 95,000 employees, Medtronic ranks among the world's largest medical tech firms. It organizes its extensive portfolio into four main divisions: Cardiovascular, Diabetes, Medical Surgical, and Neuroscience, reinforcing its position as a trusted industry leader. Medtronic's diabetes division is a key part of its business, focusing on automated insulin delivery (AID) and glucose monitoring. The company pioneered the artificial pancreas concept with its MiniMed™ insulin pumps and Guardian™ CGM systems. By developing a unified, closed-loop ecosystem, the segment aims to simplify diabetes management and lessen the daily burden for patients relying on these technologies for insulin.

For more information,

Get access to the latest updates on and

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, , and . With a , we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our , which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/diabetes-care-devices-market-worth-us61-2-billion-by-2030-with-12-3-cagr--marketsandmarkets-302558869.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili